← Back to news
🔴 BreakingNewsFDAWednesday, March 25, 2026 · March 25, 2026

FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome

WHY IT MATTERS

FDA announcement relevant to rare disease patients and caregivers.

The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

View FDA Announcement →
Read the original at FDA ↗
FDA ApprovalTreatment

Related conditions

Mucopolysaccharidosis type 2Mucopolysaccharidosis type 2, attenuated formMucopolysaccharidosis type 2, severe form

Related news

FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…